Teva Pharmaceutical Industries Limited (NYSE: TEVA) is scheduled to reveal its financial results for the third quarter on Wednesday 6th November 2024. This disclosure will take place before market open, providing investors with significant information regarding the company's performance in the last three months period.
the establishment is expected to report an estimated per share $0.66 profit for the quarter, as predicted by financial analysts on Wall Street. Furthermore, the company is anticipated to disclose a total revenue of $4.12 billion during this period.
The company's yearly performance has been analyzed by Wall Street analysts, who have projected a total revenue of $16.26 billion. Additionally, they are expecting the company to achieve a per share profit of $2.45 for the fiscal year 2024.
In the corresponding quarter of the previous year, the company's earnings report revealed a per-share income of $0.6. This significant amount was attributed to the company's remarkable total revenue of $3.85 billion generated during that specific period.
| Period | EPS Actual |
EPS Growth* |
Revenue Actual |
Revenue Growth* |
|---|---|---|---|---|
| Historical Earnings Insight | ||||
| Q2 2024 | $0.61 | +8.9% | 4.16 B | +7.4% |
| Q1 2024 | $0.48 | +20.0% | 3.82 B | +4.3% |
| Q4 2023 | $1.00 | +40.8% | 4.46 B | +14.8% |
| Q3 2023 | $0.60 | +1.7% | 3.85 B | +7.1% |
| Q2 2023 | $0.56 | -17.6% | 3.88 B | +2.4% |
| *Growth on year-over-year basis | ||||
In addition, The firm will review the third quarter financial results on 6th November 2024 at 08:00 AM eastern time, in a conference call with public.
Teva Pharmaceutical Industries Limited (TEVA) closed Friday's regular trading session at $18.45, showing a 0.05 percent upturn. During the day, TEVA shares traded between $18.37 and $18.73, with a day volume of 7.10 million shares.
